Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of persistent competition from copycat ...

Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had expected to see as of May. The company also said it now expec ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday ...

Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of ...

In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had ...

Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.

The appointment came shortly after Novo slashed its financial forecast, predicting this year’s sales will grow 8% to 14%, ...

FRANKFURT: European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to revive sales and a share price hit by worries the Wegovy maker is falling ...

Novo Nordisk has named Maziar Mike Doustdar as its new president and chief executive officer. He will take over the role on 7 August 2025, replacing Lars Fruergaard Jørgensen, who will step down the ...